Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.36 USD | -8.88% | +7.76% | -21.07% |
May. 07 | Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell | MT |
May. 07 | Top Premarket Gainers | MT |
Financials (USD)
Sales 2024 * | 323M | Sales 2025 * | 420M | Capitalization | 447M |
---|---|---|---|---|---|
Net income 2024 * | -9M | Net income 2025 * | 49M | EV / Sales 2024 * | 0.69 x |
Net cash position 2024 * | 223M | Net cash position 2025 * | 342M | EV / Sales 2025 * | 0.25 x |
P/E ratio 2024 * |
-41.9
x | P/E ratio 2025 * |
11.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Esperion Therapeutics, Inc.
1 day | -8.88% | ||
1 week | +7.76% | ||
Current month | +19.80% | ||
1 month | +28.26% | ||
3 months | -12.27% | ||
6 months | +98.32% | ||
Current year | -21.07% |
Managers | Title | Age | Since |
---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 20-12-14 |
Director of Finance/CFO | 38 | 19-12-31 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 22-04-27 | |
J. Carroll
CHM | Chairman | 74 | 22-05-31 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 20-03-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 234 M€ | +5.72% | - | |
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 2.36 | -8.88% | 8,186,716 |
24-05-16 | 2.59 | +12.61% | 10,926,980 |
24-05-15 | 2.3 | +5.50% | 6,982,026 |
24-05-14 | 2.18 | -2.24% | 4,616,605 |
24-05-13 | 2.23 | +1.83% | 4,425,062 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.07% | 491M | |
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |
- Stock Market
- Equities
- ESPR Stock